<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04181112</url>
  </required_header>
  <id_info>
    <org_study_id>H19-00782 FMT.MDRO.RCT.1</org_study_id>
    <nct_id>NCT04181112</nct_id>
  </id_info>
  <brief_title>Fecal Transplant for MDRO Decolonization</brief_title>
  <official_title>Fecal Microbiota Transplantation (FMT) for Intestinal Decolonization of Multidrug-resistant Opportunistic Pathogens</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of British Columbia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a trial designed to determine whether fecal microbiota transplantation (FMT) can
      eliminate highly drug-resistant bacteria from the intestinal tract of renal transplant
      patients. The primary goal of this study is to test whether oral gut decontamination followed
      by FMT using enema delivery will result in decolonization of the intestinal tract of renal
      transplant patients shortly after solid organ transplantation, thereby preventing difficult
      to treat post-transplant infections.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Contact the study principal investigator for the study protocol.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 4, 2019</start_date>
  <completion_date type="Anticipated">November 2023</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The elimination of the target multi-drug resistant organism (MDRO), using culture and molecular test-based screening of recipient stool, at both the 14 and 30 days post-FMT.</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare proportions, type and timing of adverse events post-FMT</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportions of recolonization over 180 days</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Timing of recolonization over 180 days</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Multi-antibiotic Resistance</condition>
  <arm_group>
    <arm_group_label>Fecal microbiota transplantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Fecal microbiota transplantation with antibiotic pre-treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>No intervention follow-up</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fecal Microbiota Transplantation (FMT)</intervention_name>
    <description>FMT using retention enema</description>
    <arm_group_label>Fecal microbiota transplantation</arm_group_label>
    <arm_group_label>Fecal microbiota transplantation with antibiotic pre-treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Renal transplant patient inclusion criteria:

          -  18 years or older

          -  Able to provide informed consent

          -  Positive for one of the target MDRO by rectal or stool culture tests

        FMT stool donor inclusion criteria:

          -  Able to provide informed consent

          -  Able to complete donor screening

          -  Able to adhere to FMT stool collection and testing procedures

        Renal transplant patient exclusion criteria:

          -  Still in hospital at week 7 following organ transplantation

          -  Pregnant or planning to become pregnant

          -  Breastfeeding

          -  Participating in another interventional or investigational study

          -  Neutropenic (ANC &lt; 0.5)

          -  Presence of colostomy or ileostomy

          -  Has an active intestinal infection

          -  Fever &gt; 38.0 or white blood count (WBC) count &gt; 15,000

          -  Are taking a non-dietary probiotic supplement

          -  Require or are expected to require systemic antimicrobial therapy other than
             Pneumocystis prophylaxis or cytomegalovirus (CMV) therapy during the study period

          -  Has a severe underlying disease with anticipated survival less than 6 months

          -  Are unable to tolerate FMT or enema for any reason, or where their physician believes
             for any reason that FMT might pose a health risk to the subject

          -  Subjects who report a history of anaphylactoid food allergy will not be excluded but
             these allergies will be noted and donors will be required to avoid ingestion of these
             foods for at least three days prior to donation

        FMT stool donor exclusion criteria:

          -  Presence of any of the following by stool examination: vancomycin-resistant
             Enterococci (VRE), Salmonella, Shigella, shiga toxin-producing E. coli, Yersinia,
             Campylobacter, extended spectrum beta-lactamase (ESBL) producing organisms or
             carbapenemase-producing Enterobacteriaceae (CRE), pathogenic ova or parasites, C.
             difficile toxin B (by PCR), or rotavirus, adenovirus and norovirus

          -  History of any type of active cancer aside from melanoma

          -  Risk factors for acquisition of HIV, syphilis, Hepatitis B, Hepatitis C, prion or any
             neurological disease as determined by the donor questionnaire

          -  History of gastrointestinal comorbidities, e.g., inflammatory bowel disease, irritable
             bowel syndrome, chronic constipation or diarrhea, or colostomy or ileostomy

          -  Receipt of blood transfusion from a country other than Canada in the preceding 6
             months

          -  Antibiotic use or any systemic immunosuppressive agents in the 3 months prior to stool
             donation

          -  Receipt of any live vaccine within 3 months prior to stool donation

          -  Any current or previous medical or psychosocial condition or behaviors which in the
             opinion of the investigator may pose risk to the recipients or the donor
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Amee Manges, MPH, PhD</last_name>
    <phone>604 707 2743</phone>
    <email>amee.manges@ubc.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Providence Health Care - St. Paul's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vancouver Coastal Health - Vancouver General Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Theodore Steiner, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 26, 2019</study_first_submitted>
  <study_first_submitted_qc>November 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 29, 2019</study_first_posted>
  <last_update_submitted>November 27, 2019</last_update_submitted>
  <last_update_submitted_qc>November 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of British Columbia</investigator_affiliation>
    <investigator_full_name>Amee Manges</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Fecal Microbiota Transplantation</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

